

# The Pattern of *rpoB* gene mutation of *Mycobacterium tuberculosis* and predictors of rifampicin resistance detected by gene Xpert MTB/Rif in Tanzania.

## Authors

Peter Richard Torokaa<sup>1,2\*</sup>, Heledy Kileo<sup>3</sup>, Loveness Urio<sup>2</sup>, Mariam R. Mbwana<sup>1,2</sup> Mariam C. Monah<sup>1,2</sup>, Sephord Saul Ntibabara<sup>1,2</sup>, Jasper Kimambo<sup>1,2</sup>, Paschal Seleman<sup>3</sup>, Collins Franklin<sup>3</sup>, Robert Balama<sup>3</sup>, Riziki M. Kisonga<sup>3</sup>, Mtebe V. Majigo<sup>4</sup>, Agricola Joachim<sup>4</sup>

## Affiliations

<sup>1</sup>Muhimbili University of Health and Allied Sciences, School of Public Health and Social Sciences, Dar es Salaam, Tanzania.

<sup>2</sup>Tanzania Field Epidemiology and Laboratory Training Program, Dar es Salaam, Tanzania.

<sup>3</sup>Ministry of Health, National TB and Leprosy Program, Dodoma Tanzania.

<sup>4</sup>Muhimbili University of Health and Allied Sciences, College of Medicine, Dar es Salaam, Tanzania

\*Corresponding Author: Peter Torokaa, Email: [peteratorokaa@gmail.com](mailto:peteratorokaa@gmail.com) (PRT)

## ABSTRACT

## Introduction

Antimicrobial resistance associated with *Mycobacterium tuberculosis* (MTB) is the challenge facing Tuberculosis (TB) management worldwide. Rifampicin resistance (RR) has been associated with the *rpoB* gene mutation. No study was conducted in Tanzania to determine the commonest mutation. The inconsistent findings from various studies support the need to determine whether

reported mutation patterns are applicable in our setting. We determined the frequency of rpoB gene mutation and factors associated with RR detected using GeneXpert MTB/Rif.

## Methods

We conducted a retrospective cross-sectional study involving data from the National Tuberculosis and Leprosy Program database from 2020 to 2022 for cases investigated using GeneXpert. Descriptive analysis was performed as the frequency for categorical variables. The chi-square test and regression analysis assessed the relationship between the independent variables and outcome. The 95% confidence interval and a significance level of  $p < 0.05$  were used to assess the association strength.

## Results

A total of 56,004 participants had status of MTB and RR. Most, 38,705/56,004 (69.11%) were male. Probe E, 89/219 (40.64%) was the predominant. Human immunodeficiency virus (HIV)-positive patients had a higher gene mutation, 134/10601 (1.26%) than HIV-negative, 306/45016 (0.68%) ( $p < 0.001$ ). Patients with both pulmonary and extra-pulmonary TB had about four times greater odds of developing rifampicin resistance (AOR 3.88, 95%CI: 1.80 – 8.32). RR was nearly nine times higher in previously treated patients than new patients (AOR 8.66, 95%CI: 6.97–10.76). HIV-positive individuals had nearly twice the odds of developing RR than HIV-negative individuals (AOR 1.91, 95%CI: 1.51 – 2.42).

## Conclusion

The rate of RR was low compared to other studies in Tanzania, with probe E mutations the most prevalent. Patients with disseminated TB, HIV co-infection and those with prior exposure to anti-

TB had more risk of RR. The findings highlight the need to strengthen surveillance of multidrug-resistant-TB among patients with a higher risk of RR.

**Keywords:** *Mycobacterium tuberculosis*, rifampicin resistance, GeneXpert, probe mutations, Tanzania

## Introduction

Multidrug-resistant *Mycobacterium tuberculosis* (MDR-TB) is the biggest challenge facing Tuberculosis (TB) care and treatment worldwide (1). MDR-TB is a major contributor to global antimicrobial resistance (AMR) and continues to pose a public health threat (1–3). MDR-TB is considered when there is resistance to isoniazid and rifampicin, with or without resistance to other first-line drugs. The main problem is rifampicin resistance, the most potent first-line treatment (1). Patients with rifampicin-resistant TB or MDR-TB require a second-line treatment regimen (4). Globally, the annual estimated number of MDR-TB or rifampicin-resistant TB cases was steady between 2015 and 2020; however, it increased in 2021. In 2021, it was estimated to be 450,000 events, a 3.1% increase from 437,000 in 2020 (1).

The World Health Organization (WHO) developed a strategy to end TB-related deaths, illnesses, and suffering by 2035 (5). It recommends accelerating the identification and enhancing treatment for MDR-TB. Apart from access to diagnosis, adequate infection control must also be implemented in the settings where patients are treated (4). To diagnose MDR-TB, WHO recommends more specific and sensitive assays like real-time polymerase chain reaction (RT-PCR), DNA microarray, and loop-mediated isothermal amplification (LAMP). These technologies determine the mutations in the genes to identify drug resistance. In some populations of HIV-infected presumptive TB

patients, the lateral flow lipoarabinomannan assay (LF-LAM) test is advised to aid in the diagnosis of TB (6).

The invention of the Xpert® MTB/RIF Assay (Cepheid, USA), which simultaneously detects the presence of *Mycobacterium tuberculosis* (MTB) and rifampicin resistance, has transformed the diagnosis of TB. Rifampicin inhibits DNA-directed RNA synthesis of MTB proteins by binding to the subunit of the bacterial DNA-dependent RNA polymerase (*rpoB*) enzyme. Rifampicin resistance has been associated with the *rpoB* gene mutation. Almost 96.1% of rifampicin-resistant MTB strains have *rpoB* mutations (7). The rifampicin resistance is the proxy sign of the MDR-TB (8,9). GeneXpert/MTB RIF is a cartridge-based, automated hemi-nested-nested real-time Polymerase Chain Reaction (PCR) system that utilizes five overlapping probes named Probe A (codons 507–511), Probe B (codons 511–518), Probe C (codons 518–523), Probe D (codons 523–529) and Probe E (codons 529–533) (10).

Studies in Africa revealed that the commonest mutation of *rpoB* occurs at probes E and D (11–13). However, the literature shows different pattern distributions of the *rpoB* gene mutation of MTB associated with drug resistance (11–13). There is a need to determine whether the findings in other studies apply to our setting due to the varied findings obtained in various geographical areas. No other study has been conducted in Tanzania to reveal the patterns of *rpoB* mutation. Due to efforts to increase access to GeneXpert MTB/RIF diagnosis in the country, there is also a need to determine the factors associated with Rifampicin-resistant TB.

## Methods

### Study design and setting

We conducted a retrospective cross-sectional study involving the Tanzania National Tuberculosis and Leprosy Program (NTLP) data collected from January 2020 through December 2022. The study covered Presumptive TB cases notified to NTLP from 26 regions of Tanzania's mainland. The NTLP is tasked with preventing tuberculosis and leprosy as serious public health concerns in Tanzania, and it was launched in 1977 as a single combined programme for the two diseases.

## Data collection

We extracted demographic and clinical data from eTL and laboratory results from gxaalert databases on 10<sup>th</sup> October, 2023 and then exported them to Microsoft Excel. The demographic data from the eTL register and laboratory results data were linked between these two databases. The identifiers used to link the two databases were patient name, health facilities, district, and year. The variables of interest from the two databases were demographic characteristics (age, gender, residence), clinical characteristics (TB treatment history, type of TB, bacillary load, HIV status), and geneXpert results.

## Data analysis

We presented the descriptive analysis with frequency distributions (%) for categorical variables and a mean was a measure of central tendency for age. Regression analyses (bivariate and multivariate) were performed to assess the relationship between demographic and clinical characteristics as independent variables and the rifampicin resistance as an outcome variable. Factors with a p-value of 0.20 in the bivariate analyses were included in the multivariable model using forward selection. The 95% confidence interval (CI) was presented, and a significance level of  $p < 0.05$  was used.

## Results

We extracted data for 112,768 nonrepeating patients tested for TB using GeneXpert. Of all, 56,662 (50.2%) had laboratory-confirmed TB. Rifampicin resistance was identified in 450/56,662 (0.8%) patients with MTB. The specific gene mutations in the *rpoB* gene of *Mycobacterium tuberculosis* were identified in the form of the missing probes, which indicated a specific mutation occurs at a specific codon in the *rpoB* gene named Probe A (codons 507–511), Probe B (codons 511–518), Probe C (codons 518–523), Probe D (codons 523–529), and Probe E (codons 529–533). Missing probes (specific *rpoB* mutation detected) were found in 219/ 450 (48.7%) samples with Rifampicin-resistant MTB, and no missing probes (no specific *rpoB* mutation detected) in 231/450 (51.3%) with Rifampicin-resistant. Rif Indeterminate were observed in 658/56,662 (1.16%) of patients with MTB and were excluded in further analysis (Fig 1).

## Fig 1. Flow chart of participants' analysis

## Demographic and clinical characteristics of study participants

A total of 56,004 participants had clear status of MTB and rifampicin resistance. Most of them, 38,705/56,004 (69.11%) were male. The age group 35- 44 years accounted for the largest cases, 13,512/56,004 (24.13%). Most participants, 55,192/56,004 (98.55%), had pulmonary TB. Participants with new TB were 53,818/56,004 (96.1%), and 45,016/56,004 (80.38%) were HIV-negative (Table 1). The Dar es Salaam region contributed 10,524/56,004 (18.79%) cases, which is higher than in any other region. The lowest number of cases were reported from the Katavi region. The regional distribution of cases is shown in Fig 2.

**Table 1. Participants' demographic and clinical characteristics (N=56,004)**

Variable	Frequency	Percent (%)
<b>Age Group (years)</b>		
<15	1765	3.15

Variable	Frequency	Percent (%)
15-24	6441	11.5
25-34	12637	22.56
35-44	13512	24.13
45-54	10460	18.68
>55	11189	19.98
Mean age (SD)	41(16.4)	
<b>Gender</b>		
Male	38705	69.11
Female	17299	30.89
<b>TB Type</b>		
Pulmonary	55192	98.55
Extra pulmonary	550	0.98
Pulmonary and extra pulmonary	262	0.47
<b>Treatment History</b>		
New patient	53818	96.1
Previous treated	2186	3.9
<b>HIV status</b>		
Positive	10601	18.93
Negative	45016	80.38
Unknown	387	0.69

126

127 **Fig 2. Map showing the proportion distribution of study participants per region**

## 128 **Pattern of specific rpoB gene mutations in MTB**

129 Specific mutations (missing probe) were detected in 219/450 (48.7%) rifampicin-resistant TB. The  
130 most prevalent mutation, 89/219 (40.64%), occurred at Probe E, followed by Probe D, 44/219  
131 (20.09%), and the least mutation, 10/219 (4.56%), occurred at Probe C. We found a mutation  
132 combination of Probe A and B, 5/219 (2.28%), Probe A and D, 2/219 (0.91%), Probe A and E 1/219  
133 (0.46%), and Probe B and E 1/219 (0.46%). One patient had a triple mutation combination at Probe  
134 A, D, and E 1/219 (0.46%) (Table 2).

135 **Table 2. Frequency and distribution of specific rpoB gene mutations (N=219)**

Probes	#Codons	Frequency	Percent (%)
Probe A	507–511	21	9.59
Probe B	511–518	39	17.81
Probe C	518–523	10	4.57
Probe D	523–529	44	20.09
Probe E	529–533	89	40.64
Probe A+B		5	2.28
Probe A+D		2	0.91
Probe A+E		1	0.46
Probe B+E		1	0.46
Probe A+D+E		1	0.46

136

## 137 The proportion of participants with no missing probe

138 Specific rpoB mutation were not detected (no missing probe) in 231/450 (51.3%) participants with  
 139 Rifampicin-resistance. We found that no missing probes were significantly higher in new TB  
 140 patients, 189/334 (56.59%) compared to previously treated patients, 42/116(36.21%) ( $p = 0.003$ ).  
 141 Patients with a very low TB bacillary load, 199/263 (75.67%), had a higher number of no missing  
 142 probes when compared with other categories ( $p < 0.001$ ). There was no statistically significant  
 143 difference of no missing probes for other variables (Table 3).

144 **Table 3. Demographic and Clinical characteristics of the number of no-missing probe study**  
 145 **participants (N=450)**

Variable	Total Rifampicin Resistant	# No missing probe	Proportion	P value
<b>Age Group</b>				
<15	6	3	50.00	
15-59	376	185	49.20	
>59	68	43	63.24	0.103
<b>Gender</b>				



Variable	Total Rifampicin Resistant	# No missing probe	Proportion	P value
Male	312	168	53.85	0.133
Female	138	63	45.65	
<b>TB Type</b>				
Pulmonary	438	224	51.14	0.59
Extra pulmonary	5	2	40.00	
Pulmonary and extra pulmonary	7	5	71.43	
<b>Treatment History</b>				
New patient	334	189	56.59	0.003
Previous treated	116	42	36.21	
<b>HIV status</b>				
Positive	134	59	44.03	0.12
Negative	306	167	54.58	
<b>Bacillary Load</b>				
High	61	10	16.39	<0.001
Medium	66	5	7.58	
Low	60	17	28.33	
Very low	263	199	75.67	

## Rifampicin resistance and participant characteristics

GeneXpert detects the mutation in the *rpoB* mutations, and the final results are provided as rifampicin-resistant. The *rpoB* gene mutation was higher in 15-59-year-old patients, 383/45,782 (0.84%) compared to other age groups ( $p = 0.047$ ). More mutations were found in patients with pulmonary and extra-pulmonary TB patients (7/262, 2.67%) than in pulmonary or extra-pulmonary alone ( $p = 0.003$ ). Furthermore, we found that previously treated patients had a higher mutation rate, 116/2186 (5.31%), compared to new patients ( $p < 0.001$ ). HIV-positive TB patients had a higher gene mutation, 134/10601 (1.26%), than HIV-negative, 306/45016 (0.68%) ( $p < 0.001$ ). Other variables like gender and point of health service showed no significant difference in gene mutation (Table 4).

158 **Table 4. Distribution of rifampicin resistance and participants' characteristics (N=56,004))**

Variable	Total participants	# Total RR	Proportion	P value
<b>Age Group</b>				
<15	1765	6	0.34	
15-59	45782	383	0.84	
>59	8457	61	0.72	0.047
<b>Gender</b>				
Male	38705	312	0.81	
Female	17299	138	0.80	0.918
<b>TB Type</b>				
Pulmonary	55192	438	0.79	
Extra pulmonary	550	5	0.91	
Pulmonary and extra pulmonary	262	7	2.67	0.003
<b>Treatment History</b>				
New patient	53818	334	0.62	
Previous treated	2186	116	5.31	<0.001
<b>HIV status</b>				
Positive	10601	134	1.26	
Negative	45016	306	0.68	<0.001
<b>Referral type</b>				
Community	46897	364	0.78	
Health facility	6167	60	0.97	
Others	2940	26	0.88	0.234

159 \*\* The frequency for HIV status is less due to unknown status.

## 160 **Predictors of rifampicin resistance**

161 Compared to pulmonary TB, patients with both pulmonary and extra-pulmonary TB had about four  
162 times greater odds of developing rifampicin resistance (AOR 3.88, 95%CI: 1.80 – 8.32). The  
163 likelihood of rifampicin resistance was nearly nine times higher in previously treated patients  
164 compared to new (AOR 8.66, 95%CI: 6.97 – 10.76). HIV-positive individuals had nearly twice the  
165 odds of developing rifampicin resistance than HIV-negative individuals (AOR 1.91, 95%CI: 1.51  
166 – 2.42) (Table 5).

167 **Table 5. Multivariate Logistic regression analysis for the predictors of Rifampicin resistance**

Characteristic	Rif. resistance n (%)	COR (95% CI)	P-value	AOR (95% CI)	P- value
<b>Age Group</b>					
<15	6 (0.34)	Ref		Ref	
15-59	383 (0.84)	2.47 (1.10 – 5.55)	0.028	2.07 (0.92 – 4.67)	0.078
>59	61 (0.72)	2.13 (0.92 – 4.93)	0.078	1.95 (0.84 – 4.54)	0.119
<b>TB Type</b>					
Pulmonary	438 (0.79)	Ref		Ref	
Extra pulmonary	5 (0.91)	1.15 (0.47 – 2.78)	0.762	1.19 (0.49 – 2.92)	0.694
Pulmonary and extra pulmonary	7 (2.67)	3.43 (1.61 -7.31)	0.001	<b>3.88 (1.80 – 8.32)</b>	<b>0.001</b>
<b>Treatment History</b>					
New patient	334 (0.62)	Ref		Ref	
Previous treated	116 (5.31)	8.97 (7.23 – 11.13)	<0.001	<b>8.66 (6.97 – 10.76)</b>	<b>&lt;0.001</b>
<b>HIV status</b>					
Negative	306 (1.26)	Ref		Ref	
Positive	134 (0.68)	1.87 (1.53 – 2.29)	<0.001	<b>1.82 (1.44 – 2.30)</b>	<b>&lt;0.001</b>
<b>Referral type</b>					
Community	364 (0.78)	Ref		Ref	
Health facility	60 (0.97)	1.25 (0.95 – 1.65)	0.104	0.83 (0.61 – 1.14)	0.250
Others	26 (0.88)	1.14 (0.76 – 1.70)	0.519	0.99 (0.66 – 1.48)	0.969

168

## 169 Discussion

170 The current study found that the most prevalent mutation in rpoB gene mutation in MTB was at  
171 probe E codon (529–533) (40.64%), followed by Probe D codon (523–529) 20.09% which was  
172 similar to studies done in Nigeria, Uganda, Pakistan, Addis Ababa Ethiopia, and Bangladesh (13–  
173 17), the similarities suggests that a significant number of low-income individuals migrating for  
174 shelters may be responsible for the spread of mutant strains within the community (18). Our findings  
175 differed from the study done in Northeast India and Enugu, South Eastern Nigeria, which revealed  
176 that the most prevalent mutations were detected at probes A and D, respectively (19,20). The  
177 differences might be attributed to geographical differences caused by the variations in the *M.*

*tuberculosis* lineage (21). According to the results of our study and previous studies, probe E is linked to the most common probe mutation in the *rpoB* gene mutation.

The study found that new TB patients had a significantly higher number of specific *rpoB* mutations not detected among those with rifampicin resistance than previously treated patients. Our finding is similar to a Northeast India study (20). This may result from an early stage of TB diagnosis, which may have a low bacillary load. No missing probe may also be triggered by various probes having varying target hybridization dynamics, which might have a higher impact after extended PCR cycles (22). Patients with low TB bacillary load also had more no-missing probes. This could mean GeneXpert testing in patients with less advanced disease and lower bacterial density (new patients) is considered less accurate in detecting rifampicin-resistant tuberculosis (23). The very low bacillary load on GeneXpert testing was shown to be substantially linked to false rifampicin resistance during the initial GeneXpert assay (22). The samples with very low bacillary load were not retested; hence, the rate of false positives for rifampicin resistance could not be determined.

The rifampicin resistance was found more in patients with both pulmonary and extra-pulmonary TB than in pulmonary or extra-pulmonary alone. In addition, patients with both pulmonary and extra-pulmonary TB had almost four times greater odds of developing rifampicin resistance. Our findings were comparable to the study done in the Debre Markos Referral Hospital Ethiopia (24). We also found that previously treated patients had significantly higher rifampicin resistance than new patients. The likelihood of rifampicin resistance was nearly nine times higher in previously treated patients than in new patients, similar to the study done in Nepal (25). Our findings support that MTB increases the ability to develop resistance when exposed to anti-TB drugs, especially in patients with poor adherence to treatment (26). In our study, the odds of developing rifampicin

resistance in previously treated patients were higher than in Somalia and other East Gojjam zone northwest Ethiopia studies, which revealed four and six times, respectively (27,28).

HIV-positive TB patients had a higher gene mutation than HIV-negative. HIV-positive individuals had nearly twice the odds of developing rifampicin resistance than HIV-negative individuals; this was similar to the studies done in northwest Ethiopia (27,29). Variations in TB/HIV co-infection have been reported in several studies, indicating challenges in diagnosis and treatment due to unusual clinical presentations and difficulties in diagnosis and treatment (30–32). This may be due to differences in TB control strategies and approaches (29). More rifampicin-resistant MTB in HIV patients might be caused by poor treatment adherence. Poor adherence to treatment is the primary factor contributing to drug resistance (25,31). This highlights the need for more surveillance and community involvement.

The study had limitations, including missing variables and being unable to confirm false positive rates for rifampicin resistance at low bacillary load. However, the large sample size of participants from all Tanzania mainland regions made the findings representative and generalisable to all regions.

## Conclusion

The rate of rifampicin resistance in our study was low compared to other studies done in Tanzania. The Probe E (codons 529–533)-related mutations were the most prevalent *rpoB* gene mutation. Patients with disseminated TB, HIV co-infection and those with prior exposure to anti-TB are associated with rifampicin resistance. The findings highlight the need to strengthen the surveillance of MDR-TB among patients identified with a higher risk of rifampicin resistance.

## Ethical considerations

Ethical approval was obtained from the MUHAS Senate Research and Publications Committee of Muhimbili University of Health and Allied Sciences, Ref. No. DA.282/298/01L/629. Approval to use the national TB program data was obtained from the NTLP Program Manager in the Ministry of Health (MoH). The data was routinely collected by health facilities providing TB care and treatment services in which ethical issues are strongly advocated.

## Author contributions

PRT, AJ, HK, MVM and LU authors contributed equally to the design. PRT, MRM, MCM, SSN, RMK, CF, RB, PS and JK did data collection and write-up of this manuscript. AJ and MVM reviewed the manuscript. All authors read and approved the final manuscript.

## Acknowledgments

We are very grateful to the Muhimbili University of Health and Allied Sciences, Ministry of Health, NTLP program, Tanzania Field Epidemiology and Laboratory program for technical support of this study.

## References

1. Global Tuberculosis report 2022. 2022. Available from: <http://apps.who.int/bookorders..>
2. Yan Shao, Dandan Yang, Weiguo Xu, Wei Lu, Honghuan Song, Yaoyao Dai, Hongbing Shen & Jianming Wang. Epidemiology of anti-tuberculosis drug resistance in a chinese population: Current situation and challenges ahead. BMC Public Health. 2011;11. <https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-11-110#Abs1>

- 241 3. Molla KA, Reta MA, Ayene YY. Prevalence of multidrug-resistant tuberculosis in East  
242 Africa: A systematic review and meta-analysis. PLoS One. 2022 Jun 1;17(6 June). <https://doi:10.1371/journal.pone.0270272>.  
243 [doi: 10.1371/journal.pone.0270272](https://doi:10.1371/journal.pone.0270272).
- 244 4. Tuberculosis: Multidrug-resistant tuberculosis (MDR-TB). [https://www.who.int/news-](https://www.who.int/news-room/questions-and-answers/item/tuberculosis-multidrug-resistant-tuberculosis-(mdr-tb))  
245 [room/questions-and-answers/item/tuberculosis-multidrug-resistant-tuberculosis-\(mdr-tb\)](https://www.who.int/news-room/questions-and-answers/item/tuberculosis-multidrug-resistant-tuberculosis-(mdr-tb))
- 246 5. World Health Organization. The End Strategy TB. End TB Strateg. 2015;53(9):1689–99.  
247 <https://www.who.int/publications-detail-redirect/WHO-HTM-TB-2015.19>
- 248 6. World Health Organization (WHO). WHO operational handbook on tuberculosis. Module 3:  
249 Diagnosis - Rapid diagnostics for tuberculosis detection 2021 update  
250 <https://apps.who.int/iris/bitstream/handle/10665/340256/9789240022614-eng.pdf>
- 251 7. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of  
252 Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient  
253 technology. J Clin Microbiol. 2010;48(1):229–37. <https://doi:10.1128/JCM.01463-09>. Epub  
254 [2009 Oct 28](https://doi:10.1128/JCM.01463-09).
- 255 8. Unit MR, Health P, Hospital D, Grove ED. The rapid diagnosis of isoniazid and rifampicin  
256 resistance in. 1998;47:189–96. J Med Microbiol. 1998 Mar;47(3):189-96.  
257 <https://doi:10.1099/00222615-47-3-189>.
- 258 9. Tao N. Risk factors for drug- - resistant tuberculosis , the association between resistant  
259 comorbidity status and drug- - patterns: a retrospective study of previously treated  
260 pulmonary tuberculosis in Shandong , China , during 2004 – 2019. 2021;1–9. [http://doi:](http://doi:10.1136/bmjopen-2020-044349)  
261 [10.1136/bmjopen-2020-044349](http://doi:10.1136/bmjopen-2020-044349).

- 262 10. Akalu GT, Tessema B, Petros B. High proportion of RR-TB and mutations conferring RR  
263 outside of the RRDR of the rpoB gene detected in GeneXpert MTB/RIF assay positive  
264 pulmonary tuberculosis cases, in Addis Ababa, Ethiopia. PLoS One. 2022;17(12  
265 December):1–18. <http://dx.doi.org/10.1371/journal.pone.0277145>
- 266 11. Reta MA, Alemnew B, Abate BB, Fourie PB. Prevalence of drug resistance-conferring  
267 mutations associated with isoniazid- and rifampicin-resistant Mycobacterium tuberculosis in  
268 Ethiopia: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2021;26:207–  
269 18. <https://doi.org/10.1016/j.jgar.2021.06.009>
- 270 12. Lavu EK, Johnson K, Banamu J, Pandey S, Carter R, Coulter C, et al. Drug-resistant  
271 tuberculosis diagnosis since Xpert ® MTB/RIF introduction in Papua New Guinea, 2012–  
272 2017 . Public Heal Action. 2019;9(1):S12–8. <https://doi:10.5588/pha.19.0005>.
- 273 13. Mboowa G, Namaganda C, Ssengooba W. Rifampicin resistance mutations in the 81 bp  
274 RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF  
275 in Kampala, Uganda: A retrospective study. BMC Infect Dis. 2014 Sep 4;14(1):1–5.  
276 <https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-14-481>
- 277 14. Ullah I, Shah AA, Basit A, Ali M, khan A, Ullah U, et al. Rifampicin resistance mutations in  
278 the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert  
279 MTB/RIF in Khyber Pakhtunkhwa, Pakistan: A retrospective study. BMC Infect Dis.  
280 2016;16(1):4–9. <http://dx.doi.org/10.1186/s12879-016-1745-2>
- 281 15. Alemu A, Tadesse M, Seid G, Mollalign H, Eshetu K, Sinshaw W, et al. Does Xpert®  
282 MTB/RIF assay give rifampicin resistance results without identified mutation? Review of  
283 cases from Addis Ababa, Ethiopia. BMC Infect Dis. 2020;20(1):1–6. <https://doi:>



[10.1186/s12879-020-4817-2](https://doi.org/10.1186/s12879-020-4817-2)

16. Uddin MKM, Rahman A, Ather MF, Ahmed T, Rahman SMM, Ahmed S, et al. Distribution and frequency of rpoB mutations detected by xpert MTB/RIF assay among beijing and non-beijing rifampicin resistant Mycobacterium tuberculosis isolates in Bangladesh. Infect Drug Resist. 2020;13:789–97. <https://www.dovepress.com/infection-and-drug-resistance-journal>
17. Ochang EA, Udoh UA, Emanghe UE, Tiku GO, Offor JB, Odo M, et al. Evaluation of rifampicin resistance and 81-bp rifampicin resistant determinant region of rpoB gene mutations of Mycobacterium tuberculosis detected with XpertMTB/Rif in Cross River State, Nigeria. Int J Mycobacteriology. 2016;5:S145–6. <http://dx.doi.org/10.1016/j.ijmyco.2016.09.007>
18. Adhikari S, Saud B, Sunar S, Ghimire S, Yadav BP. Status of rpoB gene mutation associated with rifampicin-resistant Mycobacterium tuberculosis isolated in a rural setting in Nepal. Access Microbiol. 2021;3(3):10–3. <https://DOI: 10.1099/acmi.0.000202>
19. Ugwu KO, Onah IS, Mbah GC, Ezeonu IM. Rifampicin resistance patterns and dynamics of tuberculosis and drug-resistant tuberculosis in Enugu, South Eastern Nigeria. J Infect Dev Ctries. 2020;14(9):1011–8. <https://doi:10.3855/jidc.12736>.
20. Sailo CV, Lalremruata R, Sanga Z, Fela V, Kharkongor F, Chhakchhuak Z, et al. Distribution and frequency of common mutations in rpoB gene of Mycobacterium tuberculosis detected by Xpert MTB/RIF and identification of residential areas of rifampicin resistant-TB cases: J Clin Tuberc Other Mycobact Dis. <https://doi.org/10.1016/j.jctube.2022.100342>
21. Ektefaie Y, Dixit A, Freschi L, Farhat MR. Globally diverse Mycobacterium tuberculosis resistance acquisition: a retrospective geographical and temporal analysis of whole genome

- 306 sequences. The Lancet Microbe. 2021;2(3):e96–104. [http://dx.doi.org/10.1016/S2666-](http://dx.doi.org/10.1016/S2666-5247(20)30195-6)
- 307 [5247\(20\)30195-6](http://dx.doi.org/10.1016/S2666-5247(20)30195-6)
- 308 22. Ngabonziza JCS, Decroo T, Migambi P, Habimana YM, Van Deun A, Meehan CJ, et al.
- 309 Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a
- 310 prospective observational study in Rwanda. The Lancet Microbe [Internet]. 2020;1(2):e74–
- 311 83. [http://dx.doi.org/10.1016/S2666-5247\(20\)30007-0](http://dx.doi.org/10.1016/S2666-5247(20)30007-0)
- 312 23. Variava E, Moloantoa T, Martinson NA. Discrepancies in Xpert tuberculosis testing. The
- 313 Lancet Microbe [Internet]. 2020 Jun 1 [cited 2023 Nov 30];1(2):e47–8.
- 314 <http://www.thelancet.com/article/S2666524720300331/fulltext>
- 315 24. Mulu W, Abera B, Yimer M, Hailu T, Ayele H, Abate D. Rifampicin-resistance pattern of
- 316 Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients
- 317 referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study. BMC Res
- 318 Notes. 2017;10(1):1–8. <https://doi.org/10.1186/s12879-019-3943-1>
- 319 25. Sah SK, Bhattarai PR, Shrestha A, Dhami D, Guruwacharya D, Shrestha R. Rifampicin-
- 320 resistant mycobacterium tuberculosis by genexpert mtb/rif and associated factors among
- 321 presumptive pulmonary tuberculosis patients in nepal. Infect Drug Resist. 2020;13:2911–9.
- 322 <https://www.dovepress.com/infection-and-drug-resistance-journal>
- 323 26. Berhan A, Berhan Y, Yizengaw D. A meta-analysis of drug resistant tuberculosis in Sub-
- 324 Saharan Africa: how strongly associated with previous treatment and HIV co-infection?
- 325 Ethiop J Health Sci. 2013;23(3):271–82. <https://doi:10.4314/ejhs.v23i3.10>.
- 326 27. Adane K, Ameni G, Bekele S, Abebe M, Aseffa A. Prevalence and drug resistance profile of
- 327 Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two

328 public hospitals in East Gojjam zone, northwest Ethiopia Infectious Disease epidemiology.  
 329 BMC Public Health. 2015;15(1):1–8. <https://doi.org/10.1186/s12889-015-1933-9>


330 28. Ali MM, Weldegebreal F, Kabew G, Urgesa K. Rifampicin resistant Mycobacterium  
 331 tuberculosis and associated factors among presumptive pulmonary tuberculosis patients in  
 332 Mogadishu, Somalia. SAGE Open Med. 2023;11. <https://doi.org/10.1177/20503121221148603>

333 29. Ayalew ML, Yigzaw WB, Tigabu A, Tarekegn BG. Prevalence, associated risk factors  
 334 rifampicin resistance pattern of pulmonary tuberculosis among children at debre markos  
 335 referral hospital, Northwest, Ethiopia. Infect Drug Resist. 2020;13:3863–72.  
 336 <https://doi.org/10.2147/IDR.S277222>

337 30. Yitayew YA, Bekele DM, Wondimeneh B, Menji DZA. Mother to child transmission of HIV  
 338 and associated factors among HIV exposed infants at public health facilities, Dessie town,  
 339 Ethiopia. HIV/AIDS - Res Palliat Care. 2019;11:343–50. <https://doi.org/10.2147/HIV.S221409>

340 31. Diriba K, Awulachew E, Churiso G. The magnitude of mtb and rifampicin resistance mtb  
 341 using xpert-mtb/rif assay among tuberculosis suspected patients in gedeo zone, southern  
 342 ethiopia. Infect Drug Resist. 2021;14:3961–9.  
 343 <https://doi.org/10.2147/IDR.S327607.eCollection2021>

344 32. Jaganath D, Zalwango S, Okware B, Nsereko M, Kisingo H, Malone LS, et al. Contact  
 345 investigation for active tuberculosis among child contacts in Uganda. Clin Infect Dis.  
 346 2013;57(12):1685–92. <https://doi.org/10.1093/cid/cit645>



Figure



Figure